Frequently Asked Questions
What is the CAMONX test?It is a new non-invasive test for prostate cancer. It measures changes in the composition of prostate-proximal fluids caused by the disease. The test will be offered to GPs, urologists and patients through Cambridge Oncometrix laboratory located in the UK. Based on the test results the clinician and patients can decide whether or not to perform a prostate biopsy.
How did we discover the tumormarkers?Cambridge Oncometrix has discovered and quantified a panel of substances (biomarkers) present in the prostatic gland, which change when affected by a malignant transformation. A set of non-protein biomarkers has been identified by making a direct comparison of carefully characterized prostate tissue samples taken from:
• 35 healthy men
• 45 men with Benign Prostatic Hyperplasia
• 60 men with Prostate Cancer